Table 2.

Episodes of Poor Asthma Control

N	Treatment Group		IRR* (Eso:Plb) 95% CI	P-value*
	Placebo 193	Esomeprazole 200		Eso vs Plb†	GER Interaction‡
Asthma episodes - type 1
#Events	201	224
Rate (events/person-year)	2.3	2.5	1.1 0.8, 1.5	0.66	0.93
Patients with ≥1 event, N(%)	42	42
Exacerbation Components Peak flow, 30% drop
#Events	141	180
Rate (events/person-year)	1.7	2.1	1.2 0.8, 2.0	0.35	0.99
Patients with ≥1 event, N (%)	26	28
Urgent Care
#Events	53	51
Rate (events/person-year)	0.7	0.6	0.9 0.6, 1.5	0.79	0.44
Patients with ≥1 event, N (%)	17	18
New use of oral steroids
#Events	50	48
Rate (events/person-year)	0.6	0.5	0.9 0.6, 1.3	0.62	0.84
Patients with ≥1 event, N (%)	24	21
Asthma episodes - type 2
#Events	367	383
Rate (events/person-year)	4.4	4.3	1.0 0.8, 1.3	0.87	0.19
Patients with ≥1 event, N (%)	63	60
Rescue medications
#Events	248	241
Rate (events/person-year)	3.0	2.8	0.9 0.7, 1.3	0.62	0.05
Patients with ≥1 event, N (%)	46	45
Night awakening
#Events	2,518	2,241
Rate (events/person-year)	30	28	0.9 0.6, 1.4	0.71	0.38
Patients with ≥1 event, N (%)	55	52

^*Incidence rate ratio and P-value estimated from negative binomial regression with robust variance estimates.

^†P-value for treatment effect (Esomeprazole - Placebo)

^‡P-value for modification of treatment effect by pH probe results estimated by linear regression;